HYF
Immunoprecise Antibodies (HYFT) Q3 2024 Earnings
HYFT·Reported September 16, 2024·Before market open
Immunoprecise Antibodies reported Q3 2024 revenue of $3.8M, missed analyst consensus of $5.0M by $1.2M. Diluted EPS came in at $-0.11, missed the $-0.09 consensus by $0.02.
Revenue
$3.8Mmissed by $1.2M
Consensus: $5.0MDiluted EPS
$-0.11missed by $0.02
Consensus: $-0.09
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q3 2024 Earnings FAQ
Common questions about Immunoprecise Antibodies's Q3 2024 earnings report.
Immunoprecise Antibodies (HYFT) reported Q3 2024 earnings on September 16, 2024 before market open.
Immunoprecise Antibodies reported revenue of $3.8M and diluted EPS of $-0.11 for Q3 2024.
Revenue missed the consensus estimate of $5.0M by $1.2M. EPS missed the consensus estimate of $-0.09 by $0.02.